Recent News

• 01.13.2026 - January 13, 2026 - January 14, 2026 : LifeSci Partners Corporate Access Event
• 01.13.2026 - January 13, 2026 - January 14, 2026 : LifeSci Partners Corporate Access Event
• 12.10.2025 - MediWound Reports New Clinical Data Demonstrating NexoBrid®’s Effectiveness in Preventing Traumatic Tattoos After Abrasion and Blast Injuries
• 12.03.2025 - December 3, 2025 - December 4, 2025 : International Society for Burn Injuries 2025 (ISBI 2025)
• 12.03.2025 - December 3, 2025 - December 4, 2025 : International Society for Burn Injuries 2025 (ISBI 2025)
• 11.25.2025 - MediWound Reports Third Quarter 2025 Financial Results and Provides Corporate Update
• 11.03.2025 - MediWound Successfully Completes Commissioning of Expanded GMP Manufacturing Facility for NexoBrid®
• 10.23.2025 - October 23, 2025 - October 25, 2025 : Interdisciplinary Global Diabetic Foot Conference 2025 (DFCon 2025)
• 10.23.2025 - October 23, 2025 - October 25, 2025 : Interdisciplinary Global Diabetic Foot Conference 2025 (DFCon 2025)
• 09.30.2025 - MediWound Expands Global Reach with Marketing Approval of NexoBrid® in Australia

Recent Filings

• 12.03.2025 - 144 Report of proposed sale of securities
• 11.20.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 11.20.2025 - EX-99.1 EX-99.1
• 11.14.2025 - SCHEDULE 13G Statement of Beneficial Ownership by Certain Investors
• 11.12.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 10.03.2025 - SCHEDULE 13D/A General Statement of Acquisition of Beneficial Ownership
• 09.30.2025 - 424B5 Prospectus [Rule 424(b)(5)]
• 09.30.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]